Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	transcription coregulator activity	CBFA2T2 SMARCC2 WWTR1 MED13L BCL9 SRCAP ARID1A MAML3 TP53BP1	2.81e-05	562	57	9	GO:0003712
GeneOntologyMolecularFunction	transcription coactivator activity	SMARCC2 WWTR1 BCL9 SRCAP ARID1A MAML3	2.20e-04	303	57	6	GO:0003713
GeneOntologyMolecularFunction	chromatin binding	DDX12P ANKRD17 SMARCC2 ISL1 MLLT10 MBD5 ARID1A MEF2C PRDM1	2.27e-04	739	57	9	GO:0003682
GeneOntologyMolecularFunction	protein-macromolecule adaptor activity	AP2B1 CBFA2T2 DAB2 SMARCC2 WWTR1 MED13L BCL9 SRCAP ARID1A MAML3 TP53BP1	3.79e-04	1160	57	11	GO:0030674
GeneOntologyCellularComponent	bBAF complex	SMARCC2 ARID1A	3.36e-04	10	58	2	GO:0140092
GeneOntologyCellularComponent	npBAF complex	SMARCC2 ARID1A	6.74e-04	14	58	2	GO:0071564
GeneOntologyCellularComponent	brahma complex	SMARCC2 ARID1A	6.74e-04	14	58	2	GO:0035060
GeneOntologyCellularComponent	nBAF complex	SMARCC2 ARID1A	8.86e-04	16	58	2	GO:0071565
HumanPheno	Abnormality of the hairline	HSPG2 TRIO ANKRD17 SMARCC2 MED13L SRCAP MBD5 ARID1A	7.67e-06	294	20	8	HP:0009553
HumanPheno	Congenital abnormal hair pattern	HSPG2 TRIO ANKRD17 SMARCC2 MED13L SRCAP MBD5 ARID1A	1.69e-05	327	20	8	HP:0011361
HumanPheno	Autistic behavior	HSPG2 SLITRK2 TRIO ANKRD17 SMARCC2 MED13L SRCAP MBD5 ARID1A MEF2C	8.58e-05	678	20	10	HP:0000729
HumanPheno	Abnormal eating behavior	HSPG2 SMARCC2 MBD5 ARID1A ITPR3	1.06e-04	128	20	5	HP:0100738
HumanPheno	Long eyelashes	HSPG2 SMARCC2 SRCAP MBD5 ARID1A	1.10e-04	129	20	5	HP:0000527
HumanPheno	Hyperactivity	HSPG2 SLITRK2 TRIO ANKRD17 SMARCC2 MED13L SRCAP MBD5 ARID1A	1.18e-04	558	20	9	HP:0000752
HumanPheno	Abnormality of the frontal hairline	HSPG2 TRIO ANKRD17 SMARCC2 MED13L ARID1A	1.24e-04	215	20	6	HP:0000599
HumanPheno	Hirsutism	HSPG2 TRIO SMARCC2 SRCAP MBD5 ARID1A	1.28e-04	216	20	6	HP:0001007
HumanPheno	Abnormality of the scalp hair	HSPG2 TRIO ANKRD17 SMARCC2 MED13L SRCAP MBD5 ARID1A	1.29e-04	433	20	8	HP:0100037
HumanPheno	Macrostomia	TRIO SMARCC2 MED13L SRCAP MBD5 ARID1A	1.41e-04	220	20	6	HP:0000181
HumanPheno	Wide mouth	TRIO SMARCC2 MED13L SRCAP MBD5 ARID1A	1.41e-04	220	20	6	HP:0000154
HumanPheno	Clinodactyly	HSPG2 TRIO SMARCC2 MECOM MED13L SRCAP MBD5 ARID1A MEF2C	1.47e-04	574	20	9	HP:0030084
HumanPheno	Abnormal scalp morphology	HSPG2 TRIO ANKRD17 SMARCC2 MED13L SRCAP MBD5 ARID1A	1.69e-04	450	20	8	HP:0001965
HumanPheno	Thin upper lip vermilion	TRIO ANKRD17 SMARCC2 SRCAP MBD5 ARID1A MEF2C	1.98e-04	339	20	7	HP:0000219
HumanPheno	Thin lips	TRIO ANKRD17 SMARCC2 SRCAP MBD5 ARID1A MEF2C	1.98e-04	339	20	7	HP:0000213
HumanPheno	Diagnostic behavioral phenotype	HSPG2 SLITRK2 TRIO ANKRD17 SMARCC2 MED13L SRCAP MBD5 ARID1A MEF2C	1.98e-04	747	20	10	HP:0025783
HumanPheno	Low anterior hairline	HSPG2 TRIO SMARCC2 MED13L ARID1A	2.04e-04	147	20	5	HP:0000294
HumanPheno	Abnormal lower lip morphology	HSPG2 SMARCC2 MED13L SRCAP MBD5 ARID1A	2.39e-04	242	20	6	HP:0000178
HumanPheno	Thick eyebrow	TRIO SMARCC2 MBD5 ARID1A MEF2C	2.54e-04	154	20	5	HP:0000574
HumanPheno	Abnormal 5th finger morphology	HSPG2 TRIO SMARCC2 MECOM SRCAP MBD5 ARID1A MEF2C	3.99e-04	509	20	8	HP:0004207
HumanPheno	Thick nasal alae	ANKRD17 SMARCC2 ARID1A	4.32e-04	39	20	3	HP:0009928
HumanPheno	Aggressive behavior	HSPG2 SLITRK2 TRIO SMARCC2 MED13L SRCAP MBD5 ARID1A	4.39e-04	516	20	8	HP:0000718
HumanPheno	Abnormal aggressive, impulsive or violent behavior	HSPG2 SLITRK2 TRIO SMARCC2 MED13L SRCAP MBD5 ARID1A	4.39e-04	516	20	8	HP:0006919
HumanPheno	Aplasia/Hypoplasia involving the nose	TRIO SMARCC2 MED13L SRCAP MBD5 ARID1A MEF2C	5.59e-04	401	20	7	HP:0009924
HumanPheno	Periorbital fullness	TRIO ANKRD17 SRCAP	6.61e-04	45	20	3	HP:0000629
HumanPheno	Abnormality of mouth size	HSPG2 TRIO SMARCC2 MED13L SRCAP MBD5 ARID1A	7.95e-04	425	20	7	HP:0011337
MousePheno	abnormal prenatal growth/weight/body size	HSPG2 DDX12P ACACA ZNF296 AP2B1 TRIO ZC3H13 CBFA2T2 DAB2 ANKRD17 SMARCC2 MECOM PLAGL1 ISL1 MED13L BCL9 ARID1A MEF2C PRDM1	1.15e-07	1493	47	19	MP:0004196
MousePheno	abnormal prenatal body size	HSPG2 DDX12P ACACA ZNF296 AP2B1 TRIO ZC3H13 CBFA2T2 DAB2 SMARCC2 MECOM PLAGL1 ISL1 BCL9 ARID1A PRDM1	3.43e-07	1116	47	16	MP:0010866
MousePheno	abnormal embryonic growth/weight/body size	HSPG2 DDX12P ACACA ZNF296 AP2B1 TRIO ZC3H13 DAB2 ANKRD17 SMARCC2 MECOM ISL1 MED13L BCL9 ARID1A MEF2C PRDM1	4.55e-07	1295	47	17	MP:0002088
MousePheno	abnormal embryo size	HSPG2 DDX12P ACACA ZNF296 AP2B1 TRIO ZC3H13 DAB2 SMARCC2 MECOM ISL1 BCL9 ARID1A PRDM1	1.81e-06	956	47	14	MP:0001697
MousePheno	decreased primordial germ cell number	ZNF296 CBFA2T2 PRDM1	1.22e-04	29	47	3	MP:0008392
MousePheno	effusion	HSPG2 ANKRD17 MECOM ISL1 ARID1A	1.51e-04	152	47	5	MP:0021205
MousePheno	abnormal primordial germ cell morphology	ZNF296 CBFA2T2 PRDM1	1.81e-04	33	47	3	MP:0008391
Domain	Biotin_lipoyl	ACACA DLAT	2.81e-04	9	53	2	PF00364
Domain	Biotin_lipoyl	ACACA DLAT	3.50e-04	10	53	2	IPR000089
Domain	BIOTINYL_LIPOYL	ACACA DLAT	3.50e-04	10	53	2	PS50968
Domain	Single_hybrid_motif	ACACA DLAT	5.12e-04	12	53	2	IPR011053
Domain	ATP_grasp_subdomain_1	ACACA TTLL5	1.17e-03	18	53	2	IPR013815
Domain	BRCT_dom	SMARCC2 TP53BP1	2.85e-03	28	53	2	IPR001357
Domain	ATP_grasp_subdomain_2	ACACA TTLL5	3.49e-03	31	53	2	IPR013816
Domain	CNMP_BINDING_1	KCNH6 CNBD1	3.71e-03	32	53	2	PS00888
Domain	CNMP_BINDING_2	KCNH6 CNBD1	3.71e-03	32	53	2	PS00889
Domain	cNMP_binding	KCNH6 CNBD1	4.18e-03	34	53	2	PF00027
Domain	cNMP-bd_dom	KCNH6 CNBD1	4.43e-03	35	53	2	IPR000595
Domain	CNMP_BINDING_3	KCNH6 CNBD1	4.43e-03	35	53	2	PS50042
Domain	-	RASAL3 TRIO DAB2 TNS4 SPATA13	4.93e-03	391	53	5	2.30.29.30
Domain	cNMP-bd-like	KCNH6 CNBD1	5.20e-03	38	53	2	IPR018490
Domain	PTB	DAB2 TNS4	5.75e-03	40	53	2	SM00462
Domain	PTB/PI_dom	DAB2 TNS4	6.04e-03	41	53	2	IPR006020
Domain	PH_dom-like	RASAL3 TRIO DAB2 TNS4 SPATA13	7.05e-03	426	53	5	IPR011993
Domain	-	KCNH6 CNBD1	8.20e-03	48	53	2	2.60.120.10
Domain	RmlC-like_jellyroll	KCNH6 CNBD1	9.22e-03	51	53	2	IPR014710
Domain	SH3_1	ABL2 TRIO SPATA13	1.13e-02	164	53	3	PF00018
Pathway	WP_KLEEFSTRA_SYNDROME	SMARCC2 MBD5 ARID1A	7.35e-05	29	40	3	M48076
Pubmed	A dual-activity topoisomerase complex regulates mRNA translation and turnover.	HIVEP3 HSPG2 RPAP1 ACACA ZNF296 TRIO MLLT10 MED13L BCL9 SRCAP MBD5 ARID1A SPATA13 ITPR3	2.71e-09	1105	58	14	35748872
Pubmed	Spatiotemporal profile of postsynaptic interactomes integrates components of complex brain disorders.	FKBP15 AP2B1 TRIO PRR36 NHSL2 FAM120C ANKRD17 SMARCC2 BCL9 EMSY TP53BP1 SPATA13	5.24e-08	963	58	12	28671696
Pubmed	Human transcription factor protein interaction networks.	HSPG2 NFYC DLAT ANKRD17 SMARCC2 MECOM MLLT10 BCL9 SRCAP ARID1A MEF2C EMSY TP53BP1 PRDM1	6.83e-08	1429	58	14	35140242
Pubmed	A human MAP kinase interactome.	ABL2 RASAL3 AP2B1 DAB2 NFYC ANKRD17 WWTR1 MBD5 MEF2C	1.10e-07	486	58	9	20936779
Pubmed	Large-scale characterization of HeLa cell nuclear phosphoproteins.	RPAP1 ACACA ZC3H13 CBFA2T2 DAB2 ANKRD17 SMARCC2 BCL9 EMSY TP53BP1	5.60e-07	774	58	10	15302935
Pubmed	Oct4 links multiple epigenetic pathways to the pluripotency network.	HSPG2 ANKRD17 SMARCC2 MLLT10 ARID1A TP53BP1	1.15e-06	203	58	6	22083510
Pubmed	Functional proteomics establishes the interaction of SIRT7 with chromatin remodeling complexes and expands its role in regulation of RNA polymerase I transcription.	ACACA AP2B1 ZC3H13 DLAT ANKRD17 SMARCC2 ARID1A TP53BP1 ITPR3	1.29e-06	653	58	9	22586326
Pubmed	Proteomic analyses reveal distinct chromatin-associated and soluble transcription factor complexes.	CBFA2T2 NFYC ANKRD17 SMARCC2 MECOM WWTR1 ISL1 MEF2C EMSY TP53BP1	1.40e-06	857	58	10	25609649
Pubmed	Inositol 1,4,5-trisphosphate receptors are essential for the development of the second heart field.	ISL1 MEF2C ITPR3	1.58e-06	14	58	3	21382375
Pubmed	Enterovirus 71 VP1 promotes 5-HT release by upregulating the expression of ERICH3 and methyltransferase ZC3H13.	ERICH3 ZC3H13	2.73e-06	2	58	2	35660571
Pubmed	Classic bladder exstrophy and adenocarcinoma of the bladder: Methylome analysis provide no evidence for underlying disease-mechanisms of this association.	PLAGL1 ISL1	2.73e-06	2	58	2	31296310
Pubmed	Islet-1 may function as an assistant factor for histone acetylation and regulation of cardiac development-related transcription factor Mef2c expression.	ISL1 MEF2C	2.73e-06	2	58	2	24147056
Pubmed	Resolution of cell fate decisions revealed by single-cell gene expression analysis from zygote to blastocyst.	HIVEP3 SOHLH2 ZNF296 ZC3H13 NFYC MLLT10 SRCAP ARID1A PRDM1	7.25e-06	808	58	9	20412781
Pubmed	Proteome-scale mapping of binding sites in the unstructured regions of the human proteome.	RASAL3 AP2B1 CBFA2T2 DAB2 MLLT10 BCL9 FAM186B	7.34e-06	430	58	7	35044719
Pubmed	Identification of a novel GR-ARID1a-P53BP1 protein complex involved in DNA damage repair and cell cycle regulation.	ARID1A TP53BP1	8.19e-06	3	58	2	36344675
Pubmed	PRDM1/Blimp1 downregulates expression of germinal center genes LMO2 and HGAL.	GCSAM PRDM1	8.19e-06	3	58	2	21722313
Pubmed	Reciprocal interaction between SIRT6 and APC/C regulates genomic stability.	ACACA ANKRD17 SMARCC2 SRCAP ARID1A TP53BP1 ITPR3	8.53e-06	440	58	7	34244565
Pubmed	Cardiomyocyte proliferation is suppressed by ARID1A-mediated YAP inhibition during cardiac maturation.	WWTR1 ARID1A MEF2C	8.69e-06	24	58	3	37543677
Pubmed	An Oct4-centered protein interaction network in embryonic stem cells.	FKBP15 SMARCC2 MED13L ARID1A EMSY	8.97e-06	167	58	5	20362541
Pubmed	An inducible CRISPR/Cas9 screen identifies DTX2 as a transcriptional regulator of human telomerase.	ACACA DAB2 MECOM WWTR1 BCL9	1.29e-05	180	58	5	35198878
Pubmed	SWI/SNF protein component BAF250a regulates cardiac progenitor cell differentiation by modulating chromatin accessibility during second heart field development.	ISL1 ARID1A	1.64e-05	4	58	2	22621927
Pubmed	Doc2 alpha and Munc13-4 regulate Ca(2+) -dependent secretory lysosome exocytosis in mast cells.	DAB2 UNC13D	1.64e-05	4	58	2	18354201
Pubmed	Disabled Homolog 2 Controls Prometastatic Activity of Tumor-Associated Macrophages.	DAB2 WWTR1	1.64e-05	4	58	2	32651166
Pubmed	Activity-dependent neuroprotective protein constitutes a novel element in the SWI/SNF chromatin remodeling complex.	SMARCC2 ARID1A	1.64e-05	4	58	2	17878164
Pubmed	Developmental diversification of cortical inhibitory interneurons.	PLAGL1 WWTR1 ISL1 MEF2C	1.67e-05	91	58	4	29513653
Pubmed	FCH domain only-2 organizes clathrin-coated structures and interacts with Disabled-2 for low-density lipoprotein receptor endocytosis.	AP2B1 TRIO DAB2	1.91e-05	31	58	3	22323290
Pubmed	Menin and Menin-Associated Proteins Coregulate Cancer Energy Metabolism.	FAM120C SMARCC2 SRCAP ARID1A EMSY TP53BP1	2.24e-05	341	58	6	32971831
Pubmed	The SWI/SNF complex is a mechanoregulated inhibitor of YAP and TAZ.	WWTR1 ARID1A	2.72e-05	5	58	2	30401838
Pubmed	The HSA domain of BRG1 mediates critical interactions required for glucocorticoid receptor-dependent transcriptional activation in vivo.	SMARCC2 ARID1A	2.72e-05	5	58	2	18086889
Pubmed	Spatial and temporal changes in chondroitin sulfate distribution in the sclerotome play an essential role in the formation of migration patterns of mouse neural crest cells.	HSPG2 ISL1	2.72e-05	5	58	2	9915576
Pubmed	p300/CREB binding protein-related protein p270 is a component of mammalian SWI/SNF complexes.	SMARCC2 ARID1A	2.72e-05	5	58	2	9584200
Pubmed	Differential contribution of the two waves of cardiac progenitors and their derivatives to aorta and pulmonary artery.	ISL1 MEF2C	2.72e-05	5	58	2	30951706
Pubmed	Analysis of the SWI/SNF chromatin-remodeling complex during early heart development and BAF250a repression cardiac gene transcription during P19 cell differentiation.	SMARCC2 ISL1 ARID1A	3.28e-05	37	58	3	24335282
Pubmed	Intersectin (ITSN) family of scaffolds function as molecular hubs in protein interaction networks.	AP2B1 TRIO DAB2 ANKRD17	3.65e-05	111	58	4	22558309
Pubmed	Variations in the composition of mammalian SWI/SNF chromatin remodelling complexes.	SMARCC2 ARID1A	4.08e-05	6	58	2	19650111
Pubmed	Testing for association between MeCP2 and the brahma-associated SWI/SNF chromatin-remodeling complex.	SMARCC2 ARID1A	4.08e-05	6	58	2	16940996
Pubmed	Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors.	ISL1 MEF2C	4.08e-05	6	58	2	20691899
Pubmed	The p270 (ARID1A/SMARCF1) subunit of mammalian SWI/SNF-related complexes is essential for normal cell cycle arrest.	SMARCC2 ARID1A	4.08e-05	6	58	2	16230384
Pubmed	Analysis of early C2C12 myogenesis identifies stably and differentially expressed transcriptional regulators whose knock-down inhibits myoblast differentiation.	HIVEP3 PLAGL1 MEF2C	4.49e-05	41	58	3	22147266
Pubmed	Precardiac deletion of Numb and Numblike reveals renewal of cardiac progenitors.	ISL1 MEF2C	5.71e-05	7	58	2	24843018
Pubmed	Maternal epigenetic factors in embryonic and postnatal development.	MECOM MLLT10	5.71e-05	7	58	2	36906847
Pubmed	The assembly of mammalian SWI/SNF chromatin remodeling complexes is regulated by lysine-methylation dependent proteolysis.	SMARCC2 ARID1A	7.60e-05	8	58	2	36335117
Pubmed	Epigenetic regulation by BAF (mSWI/SNF) chromatin remodeling complexes is indispensable for embryonic development.	SMARCC2 ARID1A	7.60e-05	8	58	2	26986003
Pubmed	N-cadherin prevents the premature differentiation of anterior heart field progenitors in the pharyngeal mesodermal microenvironment.	ISL1 MEF2C	7.60e-05	8	58	2	25367124
Pubmed	Cooperative interaction of Nkx2.5 and Mef2c transcription factors during heart development.	ISL1 MEF2C	7.60e-05	8	58	2	19035347
Pubmed	Proximity-dependent Mapping of the Androgen Receptor Identifies Kruppel-like Factor 4 as a Functional Partner.	SMARCC2 MED13L BCL9 ARID1A EMSY	8.59e-05	268	58	5	33640491
Pubmed	Coffin-Siris Syndrome	SMARCC2 ARID1A	9.77e-05	9	58	2	23556151
Pubmed	Mammalian SWI/SNF--a subunit BAF250/ARID1 is an E3 ubiquitin ligase that targets histone H2B.	SMARCC2 ARID1A	9.77e-05	9	58	2	20086098
Pubmed	The BAF chromatin complex component SMARCC1 does not mediate GLI transcriptional repression of Hedgehog target genes in limb buds.	SMARCC2 ARID1A	9.77e-05	9	58	2	37805104
Pubmed	Coordinate Nodal and BMP inhibition directs Baf60c-dependent cardiomyocyte commitment.	ISL1 MEF2C	9.77e-05	9	58	2	24186978
Pubmed	Retinal ganglion cell axon sorting at the optic chiasm requires dystroglycan.	HSPG2 ISL1	9.77e-05	9	58	2	30149005
Pubmed	Rapid and phosphoinositol-dependent binding of the SWI/SNF-like BAF complex to chromatin after T lymphocyte receptor signaling.	SMARCC2 ARID1A	9.77e-05	9	58	2	9845365
Pubmed	ZMYM3 regulates BRCA1 localization at damaged chromatin to promote DNA repair.	SMARCC2 SRCAP ARID1A TP53BP1	1.18e-04	150	58	4	28242625
Pubmed	Novel SWI/SNF chromatin-remodeling complexes contain a mixed-lineage leukemia chromosomal translocation partner.	SMARCC2 ARID1A	1.22e-04	10	58	2	12665591
Pubmed	A methylation-mediator complex in hormone signaling.	SMARCC2 ARID1A	1.22e-04	10	58	2	14729568
Pubmed	Cardiac neural crest and outflow tract defects in Lrp6 mutant mice.	ISL1 MEF2C	1.22e-04	10	58	2	19705442
Pubmed	Functional selectivity of recombinant mammalian SWI/SNF subunits.	SMARCC2 ARID1A	1.49e-04	11	58	2	11018012
Pubmed	Delta-like ligand 4-mediated Notch signaling controls proliferation of second heart field progenitor cells by regulating Fgf8 expression.	ISL1 MEF2C	1.49e-04	11	58	2	32778568
Pubmed	Canonical Wnt signaling is a positive regulator of mammalian cardiac progenitors.	ISL1 MEF2C	1.49e-04	11	58	2	17576928
Pubmed	Genome-wide impact of the BRG1 SWI/SNF chromatin remodeler on the transforming growth factor beta transcriptional program.	SMARCC2 ARID1A	1.49e-04	11	58	2	18003620
Pubmed	Post-transcriptional Regulation of Nkx2-5 by RHAU in Heart Development.	ISL1 MEF2C	1.49e-04	11	58	2	26489465
Pubmed	Developmental origin of the neuronal subtypes that comprise the amygdalar fear circuit in the mouse.	ISL1 MEF2C	1.78e-04	12	58	2	20484636
Pubmed	Disruption of spatiotemporal hypoxic signaling causes congenital heart disease in mice.	ISL1 MEF2C	1.78e-04	12	58	2	28436940
Pubmed	PRDM paralogs antagonistically balance Wnt/β-catenin activity during craniofacial chondrocyte differentiation.	MECOM BCL9	1.78e-04	12	58	2	35132438
Pubmed	Hand1 regulates cardiomyocyte proliferation versus differentiation in the developing heart.	ISL1 MEF2C	1.78e-04	12	58	2	17050624
Pubmed	Kindlin-2 Is Essential for Preserving Integrity of the Developing Heart and Preventing Ventricular Rupture.	HSPG2 WWTR1	1.78e-04	12	58	2	30883226
Pubmed	SYT associates with human SNF/SWI complexes and the C-terminal region of its fusion partner SSX1 targets histones.	SMARCC2 ARID1A	1.78e-04	12	58	2	11734557
Pubmed	Loss of BAF (mSWI/SNF) Complexes Causes Global Transcriptional and Chromatin State Changes in Forebrain Development.	SMARCC2 ARID1A MEF2C	1.79e-04	65	58	3	26655900
Pubmed	Prdm1 functions in the mesoderm of the second heart field, where it interacts genetically with Tbx1, during outflow tract morphogenesis in the mouse embryo.	ISL1 PRDM1	2.11e-04	13	58	2	24821700
Pubmed	Fanconi anemia protein, FANCA, associates with BRG1, a component of the human SWI/SNF complex.	SMARCC2 ARID1A	2.11e-04	13	58	2	11726552
Pubmed	Separation and Quantification of Some Alkaloids from Fumaria parviflora by Capillary Isotachophoresis1.	SMARCC2 ARID1A	2.11e-04	13	58	2	17340523
Pubmed	Global gene expression analysis in fetal mouse ovaries with and without meiosis and comparison of selected genes with meiosis in the testis.	RBPMS2 ANKRD17	2.11e-04	13	58	2	17431699
Pubmed	Graded mesoderm assembly governs cell fate and morphogenesis of the early mammalian heart.	ISL1 MEF2C	2.11e-04	13	58	2	36736300
Pubmed	Identification of Novel Nuclear Factor of Activated T Cell (NFAT)-associated Proteins in T Cells.	NFYC SMARCC2 ARID1A TP53BP1	2.27e-04	178	58	4	27637333
Pubmed	Purification and biochemical heterogeneity of the mammalian SWI-SNF complex.	SMARCC2 ARID1A	2.46e-04	14	58	2	8895581
Pubmed	Lamin A/C-dependent chromatin architecture safeguards naïve pluripotency to prevent aberrant cardiovascular cell fate and function.	ISL1 MEF2C	2.46e-04	14	58	2	36333314
Pubmed	Kinetic analysis of npBAF to nBAF switching reveals exchange of SS18 with CREST and integration with neural developmental pathways.	SMARCC2 ARID1A	2.83e-04	15	58	2	23785148
Pubmed	An essential switch in subunit composition of a chromatin remodeling complex during neural development.	SMARCC2 ARID1A	2.83e-04	15	58	2	17640523
Pubmed	The murine SNF5/INI1 chromatin remodeling factor is essential for embryonic development and tumor suppression.	SMARCC2 ARID1A	2.83e-04	15	58	2	11263494
Pubmed	CHARGE syndrome-associated CHD7 acts at ISL1-regulated enhancers to modulate second heart field gene expression.	ISL1 MEF2C	2.83e-04	15	58	2	37052590
Pubmed	Mammalian SWI/SNF complexes promote MyoD-mediated muscle differentiation.	SMARCC2 ARID1A	2.83e-04	15	58	2	11175787
Pubmed	Trio controls the mature organization of neuronal clusters in the hindbrain.	TRIO ISL1	2.83e-04	15	58	2	17898204
Pubmed	PBAF chromatin-remodeling complex requires a novel specificity subunit, BAF200, to regulate expression of selective interferon-responsive genes.	SMARCC2 ARID1A	2.83e-04	15	58	2	15985610
Pubmed	Regulation of dendritic development by neuron-specific chromatin remodeling complexes.	SMARCC2 ARID1A	2.83e-04	15	58	2	17920018
Pubmed	The AERO system: a 3D-like approach for recording gene expression patterns in the whole mouse embryo.	SOHLH2 WWTR1 ISL1 PRDM1	2.97e-04	191	58	4	24146773
Pubmed	Interaction network of human early embryonic transcription factors.	SMARCC2 MECOM BCL9 ARID1A EMSY	3.01e-04	351	58	5	38297188
Pubmed	SRCAP complex promotes lung cancer progression by reprograming the oncogenic transcription of Hippo-YAP/TAZ signaling pathway.	ACACA WWTR1 SRCAP ARID1A EMSY TP53BP1	3.04e-04	549	58	6	38280479
Pubmed	A novel nuclear receptor corepressor complex, N-CoR, contains components of the mammalian SWI/SNF complex and the corepressor KAP-1.	SMARCC2 SRCAP	3.23e-04	16	58	2	11013263
Pubmed	Nf2-Yap signaling controls the expansion of DRG progenitors and glia during DRG development.	WWTR1 ISL1	3.23e-04	16	58	2	25433207
Pubmed	Role of the Sin3-histone deacetylase complex in growth regulation by the candidate tumor suppressor p33(ING1).	SMARCC2 ARID1A	3.23e-04	16	58	2	11784859
Pubmed	Mutations in Hnrnpa1 cause congenital heart defects.	ISL1 MEF2C	3.23e-04	16	58	2	29367466
Pubmed	SWI/SNF complexes are required for retinal pigmented epithelium differentiation and for the inhibition of cell proliferation and neural differentiation programs.	SMARCC2 ISL1	3.23e-04	16	58	2	37522516
Pubmed	Tbx20 dose-dependently regulates transcription factor networks required for mouse heart and motoneuron development.	ISL1 MEF2C	3.23e-04	16	58	2	15843409
Pubmed	A genome-wide meta-analysis of genetic variants associated with allergic rhinitis and grass sensitization and their interaction with birth order.	ABL2 EMSY	3.23e-04	16	58	2	22036096
Pubmed	Identification of a polymorphic, neuron-specific chromatin remodeling complex.	SMARCC2 ARID1A	3.66e-04	17	58	2	12368262
Pubmed	Nucleoredoxin sustains Wnt/β-catenin signaling by retaining a pool of inactive dishevelled protein.	HSPG2 ISL1	3.66e-04	17	58	2	20970343
Pubmed	Identification of novel SHOX target genes in the developing limb using a transgenic mouse model.	ISL1 MEF2C	3.66e-04	17	58	2	24887312
Pubmed	The human SWI/SNF-B chromatin-remodeling complex is related to yeast rsc and localizes at kinetochores of mitotic chromosomes.	SMARCC2 ARID1A	3.66e-04	17	58	2	11078522
Pubmed	Yap controls notochord formation and neural tube patterning by integrating mechanotransduction with FoxA2 and Shh expression.	WWTR1 ISL1	3.66e-04	17	58	2	37315133
Pubmed	Mutation of p107 exacerbates the consequences of Rb loss in embryonic tissues and causes cardiac and blood vessel defects.	ISL1 MEF2C	3.66e-04	17	58	2	19706423
Interaction	TOP3B interactions	HIVEP3 HSPG2 RPAP1 ACACA ZNF296 TRIO FAM120C DLAT ANKRD17 MLLT10 MED13L BCL9 SRCAP MBD5 ARID1A TP53BP1 SPATA13 ITPR3	8.31e-08	1470	58	18	int:TOP3B
Interaction	POU5F1 interactions	HSPG2 NFYC ANKRD17 SMARCC2 MLLT10 ARID1A EMSY TP53BP1 ITPR3 CC2D2B	5.77e-06	584	58	10	int:POU5F1
Interaction	ETS1 interactions	SMARCC2 SRCAP ARID1A EMSY PRDM1	2.55e-05	121	58	5	int:ETS1
Interaction	SMG7 interactions	FAM120C ANKRD17 MECOM WWTR1 MLLT10 BCL9 ARID1A	3.51e-05	319	58	7	int:SMG7
Interaction	FAM193A interactions	FKBP15 AP2B1 FAM120C ANKRD17	5.20e-05	71	58	4	int:FAM193A
Interaction	KLHDC7B interactions	RBPMS2 NFYC TP53BP1	7.04e-05	28	58	3	int:KLHDC7B
GeneFamily	Zinc fingers C2H2-type\|PR/SET domain family	MECOM PRDM1	5.44e-04	17	37	2	1197
ToppCell	Parenchymal-NucSeq\|Parenchymal / Cell types per location group and 10X technology with lineage, and cell group designations	ACACA TRIO MECOM MED13L MBD5 KIF13A MAML3	6.31e-09	198	57	7	1996373bdccc55aac347d349bd22f6aad6d0c668
ToppCell	Brain_organoid-organoid_Kanton_Nature-Organoid-1M-Mesenchymal\|Organoid-1M / Sample Type, Dataset, Time_group, and Cell type.	HSPG2 SLITRK2 DAB2 WWTR1 MEF2C ITPR3	1.74e-07	193	57	6	e1de67ddada87229f5db0ec193a6da8745a86a64
ToppCell	Brain_organoid-organoid_Kanton_Nature-Organoid-1M-Mesenchymal-choroid_plexus/mesenchymal-like_cells\|Organoid-1M / Sample Type, Dataset, Time_group, and Cell type.	HSPG2 SLITRK2 DAB2 WWTR1 MEF2C ITPR3	1.74e-07	193	57	6	b6f5a85210e60798205eaf5884cdb540f549d08a
ToppCell	Bronchial-NucSeq\|Bronchial / Cell types per location group and 10X technology with lineage, and cell group designations	HIVEP3 ACACA MECOM MED13L MBD5 MAML3	1.91e-07	196	57	6	ab53c742866945545a92e2e61850d63c80d9a2a6
ToppCell	Tracheal-NucSeq\|Tracheal / Cell types per location group and 10X technology with lineage, and cell group designations	ACACA TRIO MECOM MED13L MBD5 MAML3	2.09e-07	199	57	6	94b94b17ca18b8dc27b91da1f2ccf89e03cc7035
ToppCell	3'-GW_trimst-1-LargeIntestine-Endothelial-blood_vessel_EC-Fetal_venous_EC\|GW_trimst-1 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	HSPG2 DAB2 MECOM WWTR1 MEF2C	4.82e-06	193	57	5	0f2967afbbf4e538b63f985c0acc2e5d9aab7589
ToppCell	IPF-Endothelial-VE_Peribronchial\|Endothelial / Disease state, Lineage and Cell class	HSPG2 ABL2 TRIO MECOM MEF2C	5.46e-06	198	57	5	b8bd1ba268480f54451648e01631b615a3401144
ToppCell	BALF-PFMC-Severe-critical_progression_d12-22_with-steroid-Myeloid-Dendritic-plasmacytoid_dendritic_cell-DC_c4-LILRA4\|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k)	SPATC1 ZNF296 MAML3 GCSAM	3.21e-05	141	57	4	3fa3d2a8ebd9c285168ecea6db9cad74d3a3e85a
ToppCell	BALF-PFMC-Severe-critical_progression_d12-22_with-steroid-Myeloid-Dendritic-plasmacytoid_dendritic_cell\|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k)	SPATC1 ZNF296 MAML3 GCSAM	3.21e-05	141	57	4	cabb5b8c0874813c713508af2ac620ab0d61ab6f
ToppCell	3'-GW_trimst-1-LargeIntestine-Epithelial-neuro-epithelial-Progenitor_(NEUROG3+)\|GW_trimst-1 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	KCNH6 ZNF296 PRR36 ISL1	4.41e-05	153	57	4	20786807bba3bcd70ce744f8b6454e064199ed9f
ToppCell	droplet-Kidney-KIDNEY-30m-Lymphocytic-Epcam____proximal_tube_epithelial_cell\|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	HIVEP3 ACACA MBD5 KIF13A	5.00e-05	158	57	4	1d78578dc1f8ba43dacdccae1082c0b9d749f64d
ToppCell	droplet-Limb_Muscle-nan-24m-Myeloid-chondrocyte-like\|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	HIVEP3 KCNH6 PXT1 UNC13D	5.25e-05	160	57	4	984990be02642a562f0c60ea99c01f005e7c02c2
ToppCell	facs-Marrow-KLS-24m-Lymphocytic-naive_B_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	RBPMS2 DAB2 ISL1 EMSY	5.65e-05	163	57	4	b83a35c4426d66b5734a98fa6c72b345fe462030
ToppCell	facs-Marrow-KLS-24m-Lymphocytic-naive_B_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	RBPMS2 DAB2 ISL1 EMSY	5.65e-05	163	57	4	c20ca9b6b4170ebcb0e66eef3e5d8ebff22b1a91
ToppCell	facs-Marrow-KLS-24m-Lymphocytic\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	RBPMS2 DAB2 ISL1 EMSY	5.78e-05	164	57	4	d2b5f51af7fcffddebe997ee302bacbd85d76852
ToppCell	TCGA-Ovary-Primary_Tumor-Ovarian_Carcinoma-Serous_Cystadenocarcinoma-5\|TCGA-Ovary / Sample_Type by Project: Shred V9	MBD5 ARID1A FAM186B MAML3	6.06e-05	166	57	4	32d2eaf8a5d03881bf74d680825af2d5110b082d
ToppCell	BAL-Severe-Myeloid-cDC-cDC-cDC_4\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	NHSL2 MAML3 MEF2C CC2D2B	6.35e-05	168	57	4	d60f7cd8269f373827f49c7785002cb38e4570a9
ToppCell	BAL-Severe-Myeloid-cDC-cDC-cDC_4\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	NHSL2 MAML3 MEF2C CC2D2B	6.50e-05	169	57	4	ccd98f9005aa0a88bd49f153be4e7200cc3dd0ac
ToppCell	PBMC_fresh-frozen-Mild-Moderate_progression_d12-25-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c04-ANXA2\|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k)	SLITRK2 DLAT GCSAM PRDM1	6.50e-05	169	57	4	01a24a8817628125bd004b2be68ffa62c7111f6e
ToppCell	Adult-Epithelial-alveolar_epithelial_cell_type_2/Club-like_(AT2/Club-like)-D231\|Adult / Lineage, Cell type, age group and donor	KCNH6 ACACA MECOM WWTR1	6.65e-05	170	57	4	269dee5abca9f6aa079f116f0d8f1d198604d9d4
ToppCell	COVID-19-kidney-AQP1+SLC14A1+EC\|COVID-19 / Disease (COVID-19 only), tissue and cell type	HSPG2 MECOM WWTR1 MEF2C	8.12e-05	179	57	4	1ce8d18f63e8dd2d3db41fbeca4601bd3b305fba
ToppCell	droplet-Liver-LIVER_HEP-30m\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	HSPG2 MECOM ISL1 MEF2C	8.29e-05	180	57	4	dd1b10c7f5a0fbc63163844ca1882884a24a84d3
ToppCell	droplet-Liver-LIVER_HEP\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	HSPG2 MECOM ISL1 MEF2C	8.29e-05	180	57	4	423454e3390080ae03bb3cbb267255ebfe4df080
ToppCell	BALF-PFMC-Severe-critical_progression_d12-22_with-steroid-Myeloid-Monocytic-Nonclassical_Monocyte\|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k)	SPATC1 OXER1 TRIO DAB2	8.84e-05	183	57	4	36b194e366a14ebc4df187bf31c902be3797bfcc
ToppCell	TCGA-Colorectal-Primary_Tumor-Colorectal_Adenocarcinoma-Colon_Adenocarcinoma-7\|TCGA-Colorectal / Sample_Type by Project: Shred V9	TRIO ZC3H13 CBFA2T2 SPATA13	9.81e-05	188	57	4	14bc73cf79c79c9f208369fd8d498e5b26e0114d
ToppCell	COVID-19-Heart-EC_(POSTN)\|COVID-19 / Disease (COVID-19 only), tissue and cell type	HSPG2 NHSL2 MECOM WWTR1	1.00e-04	189	57	4	7346c1112e2e155dbd71b6dbc80e680fd262a691
ToppCell	droplet-Tongue-nan-3m-Epithelial-filiform\|Tongue / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ERICH3 ISL1 KIF13A SPATA13	1.02e-04	190	57	4	251e3a33041023bfc4b547c7eb68cfb8f421636f
ToppCell	droplet-Tongue-TONGUE-1m-Epithelial-filiform\|Tongue / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ERICH3 ISL1 KIF13A SPATA13	1.02e-04	190	57	4	8a53f4d3c9aca45b5826f53f7dcdfb8bc8280acb
ToppCell	COVID-19-Heart-EC_(POSTN)\|Heart / Disease (COVID-19 only), tissue and cell type	HSPG2 NHSL2 MECOM WWTR1	1.06e-04	192	57	4	c0c34785a7bdf461722029b322e9184e3d9b3c26
ToppCell	human_hepatoblastoma-Tumor_cells\|World / Sample and Cell Type and Tumor Cluster (all cells)	CBFA2T2 PLAGL1 MED13L MBD5	1.06e-04	192	57	4	916fbec1c7ab7969bda711886ac88e877e30c280
ToppCell	renal_cortex_nuclei\|World / Celltypes from Cells and Nuclei per compartment and clinical group	TRIO ANKRD17 MED13L MBD5	1.06e-04	192	57	4	e8cc4d08fcfceeab75a02558817e4ccd7dbafe3a
ToppCell	droplet-Liver-LIVER_HEP-30m-Endothelial\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	HSPG2 MECOM WWTR1 MEF2C	1.09e-04	193	57	4	826b8dd801298b3e0cd76232feae5a14026b8806
ToppCell	RV-10._Endothelium_II\|RV / Chamber and Cluster_Paper	HSPG2 NHSL2 MECOM WWTR1	1.09e-04	193	57	4	01c2df9206f1527c578e808978e58196c35e72f5
ToppCell	nucseq\|World / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	TRIO ANKRD17 MED13L MAML3	1.09e-04	193	57	4	779276e775cb2492e8dd36436295a536084a6415
ToppCell	droplet-Liver-LIVER_HEP-30m-Endothelial-endothelial_cell_of_hepatic_sinusoid\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	HSPG2 MECOM WWTR1 MEF2C	1.09e-04	193	57	4	87d3a577d37fb0cb4b6313c596310de452bc3872
ToppCell	10x_3'_v2v3-Non-neoplastic-Myeloid-TAM-MG-TAM-MG_pro-infl_II\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	ABL2 MEF2C SPATA13 PRDM1	1.13e-04	195	57	4	562e4c0e4e81f6303e57b846da71d1667fc35963
ToppCell	wk_15-18-Epithelial-Distal_epithelial-type_II_pneumocyte\|wk_15-18 / Celltypes from embryonic and fetal-stage human lung	HSPG2 PRR36 MECOM ITPR3	1.13e-04	195	57	4	0e3aac1b1a1fd483f5fb9a394eb90c0e1ce63542
ToppCell	10x_3'_v2v3-Non-neoplastic-Myeloid-TAM-MG-TAM-MG_pro-infl_II-G\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	ABL2 MEF2C SPATA13 PRDM1	1.13e-04	195	57	4	fa8ac154e5aebc26463ff84f0ad1038095770bc6
ToppCell	distal-Endothelial-Bronchial_Vessel_2-3\|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	HSPG2 MECOM WWTR1 MEF2C	1.17e-04	197	57	4	9fcfbfbe78e8fe90c76eb37a58ed9dc8ece652a1
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Myeloid-TAM-MG-TAM-MG_aging_sig-F\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	HIVEP3 ABL2 FAM186B MEF2C	1.22e-04	199	57	4	b0a906586e58009f5ed9272fc29ba28e49c85ee6
ToppCell	5'-GW_trimst-2-LargeIntestine-Endothelial\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	HSPG2 NHSL2 MECOM MEF2C	1.22e-04	199	57	4	f0bf75bfae7b288ecb6801be458b03ebd0108ea7
ToppCell	Hematolymphoid-Microglia-TYROBP----L1-3\|Hematolymphoid / cells hierarchy compared to all cells using T-Statistic	HIVEP3 MED13L MAML3 MEF2C	1.24e-04	200	57	4	a20dce14f94777687aad57d6fbe3258ad376f63f
ToppCell	TCGA-Bile_Duct-Primary_Tumor-Cholangiocarcinoma-Intrahepatic\|TCGA-Bile_Duct / Sample_Type by Project: Shred V9	ABL2 AP2B1 TRIO BCL9	1.24e-04	200	57	4	1fa8422fd820d21e285a7e7c4c6fbd8b7277d2af
ToppCell	Hematolymphoid-Microglia-TYROBP--\|Hematolymphoid / cells hierarchy compared to all cells using T-Statistic	HIVEP3 MED13L MAML3 MEF2C	1.24e-04	200	57	4	dc344b3ec51d506952e38f0b3a7795d65f9dd4eb
ToppCell	Hematolymphoid-Microglia-TYROBP-\|Hematolymphoid / cells hierarchy compared to all cells using T-Statistic	HIVEP3 MED13L MAML3 MEF2C	1.24e-04	200	57	4	3bba5219453322198e8fdb0921d5f8c403598751
ToppCell	Hematolymphoid-Microglia\|Hematolymphoid / cells hierarchy compared to all cells using T-Statistic	HIVEP3 MED13L MAML3 MEF2C	1.24e-04	200	57	4	21bcca3b670fe9bac034aef2275d3de4a9a73e2b
ToppCell	Hematolymphoid-Microglia-TYROBP---\|Hematolymphoid / cells hierarchy compared to all cells using T-Statistic	HIVEP3 MED13L MAML3 MEF2C	1.24e-04	200	57	4	a8646d0fca99f10827c2d2a12e584660ef7155f1
ToppCell	5'-GW_trimst-2-LargeIntestine-Endothelial-blood_vessel_EC\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	HSPG2 NHSL2 MECOM MEF2C	1.24e-04	200	57	4	90061284a80d29a4ca6078f578e13d32b8cc80e1
ToppCell	Hematolymphoid-Microglia-TYROBP\|Hematolymphoid / cells hierarchy compared to all cells using T-Statistic	HIVEP3 MED13L MAML3 MEF2C	1.24e-04	200	57	4	33036d21c1c82109284473a515c4f890b33fdd5c
Drug	Vancomycin hydrochloride [1404-93-9]; Down 200; 2.6uM; MCF7; HT_HG-U133A	VPS9D1 HSPG2 TRIO CBFA2T2 WWTR1 ARID1A EMSY	6.53e-07	196	58	7	4423_DN
Drug	Letrozole [112809-51-5]; Down 200; 14uM; MCF7; HT_HG-U133A	HIVEP3 PRR36 FAM120C TTLL5 ARID1A KIF13A EMSY	7.48e-07	200	58	7	4824_DN
Drug	Tiletamine hydrochloride; Down 200; 15.4uM; MCF7; HT_HG-U133A	HSPG2 ZC3H13 CBFA2T2 TTLL5 PLAGL1 EMSY	9.92e-06	194	58	6	6516_DN
Drug	Trimeprazine tartrate [4330-99-8]; Up 200; 5.4uM; MCF7; HT_HG-U133A	HIVEP3 PRR36 PLAGL1 MLLT10 BCL9 EMSY	1.02e-05	195	58	6	3478_UP
Drug	Pramoxine hydrochloride [637-58-1]; Down 200; 12.2uM; MCF7; HT_HG-U133A	HIVEP3 HSPG2 RPAP1 PRR36 TTLL5 KIF13A	1.02e-05	195	58	6	4368_DN
Drug	Hexamethonium dibromide dihydrate [55-97-0]; Up 200; 10uM; MCF7; HT_HG-U133A	TRIO FAM120C ZC3H13 ISL1 SRCAP KIF13A	1.05e-05	196	58	6	4965_UP
Drug	Esculin Hydrate [531-75-9]; Down 200; 11.8uM; MCF7; HT_HG-U133A	HSPG2 TRIO PLAGL1 WWTR1 SRCAP ARID1A	1.05e-05	196	58	6	3390_DN
Drug	Sulfamethizole [144-82-1]; Down 200; 14.8uM; PC3; HT_HG-U133A	HIVEP3 FKBP15 AP2B1 FAM120C MLLT10 BCL9	1.11e-05	198	58	6	5798_DN
Drug	Tetrahydroalstonine [6474-90-4]; Down 200; 11.4uM; HL60; HG-U133A	RPAP1 ANKRD17 SMARCC2 MED13L ARID1A MAML3	1.15e-05	199	58	6	1756_DN
Drug	2-propylpentanoic acid; Up 200; 50uM; MCF7; HT_HG-U133A	VPS9D1 PRR36 ZC3H13 CBFA2T2 KIF13A PRDM1	1.15e-05	199	58	6	5219_UP
Drug	Methylatropine nitrate [52-88-0]; Down 200; 11uM; MCF7; HT_HG-U133A	HIVEP3 HSPG2 AP2B1 FAM120C TTLL5 MECOM	1.15e-05	199	58	6	6495_DN
Drug	Diphenylpyraline hydrochloride [132-18-3]; Down 200; 12.6uM; MCF7; HT_HG-U133A	VPS9D1 AP2B1 FAM120C ARID1A MEF2C EMSY	1.15e-05	199	58	6	4765_DN
Drug	trichostatin A, Streptomyces sp.; Down 200; 1uM; PC3; HT_HG-U133A	AP2B1 NFYC MED13L ARID1A EMSY	8.13e-05	174	58	5	7105_DN
Drug	Thioguanosine [85-31-4]; Up 200; 12.6uM; MCF7; HT_HG-U133A	TRIO ZC3H13 SRCAP MEF2C EMSY	1.00e-04	182	58	5	4989_UP
Drug	Thonzonium bromide [553-08-2]; Up 200; 6.8uM; MCF7; HT_HG-U133A	HIVEP3 VPS9D1 ABL2 SRCAP MEF2C	1.14e-04	187	58	5	5678_UP
Drug	Tubocurarine chloride pentahydrate (+) [6989-98-6]; Up 200; 5.2uM; MCF7; HT_HG-U133A	CBFA2T2 DAB2 MECOM PLAGL1 SRCAP	1.23e-04	190	58	5	2887_UP
Drug	chlorpromazine hydrochloride; Down 200; 1uM; MCF7; HT_HG-U133A	TRIO CBFA2T2 TTLL5 MECOM PLAGL1	1.26e-04	191	58	5	5214_DN
Drug	5707885; Down 200; 50uM; PC3; HT_HG-U133A	HIVEP3 PRR36 BCL9 SRCAP MEF2C	1.26e-04	191	58	5	6390_DN
Drug	haloperidol; Down 200; 10uM; MCF7; HT_HG-U133A	AP2B1 TRIO TTLL5 NFYC EMSY	1.26e-04	191	58	5	5200_DN
Drug	Naproxen [22204-53-1]; Down 200; 17.4uM; MCF7; HT_HG-U133A	RPAP1 TTLL5 WWTR1 BCL9 EMSY	1.26e-04	191	58	5	1706_DN
Drug	Ald1.1-H_000455; Up 200; 10uM; PC3; HT_HG-U133A	TRIO FAM120C SRCAP ARID1A EMSY	1.26e-04	191	58	5	7547_UP
Drug	Midodrine hydrochloride [3092-17-9]; Down 200; 13.8uM; MCF7; HT_HG-U133A	AP2B1 TRIO TTLL5 BCL9 SRCAP	1.26e-04	191	58	5	2250_DN
Drug	GSK-3 Inhibitor IX; Down 200; 0.5uM; PC3; HT_HG-U133A	AP2B1 SMARCC2 WWTR1 MED13L EMSY	1.29e-04	192	58	5	7106_DN
Drug	SC 19220; Down 200; 10uM; PC3; HT_HG-U133A	HSPG2 CBFA2T2 TTLL5 SRCAP EMSY	1.29e-04	192	58	5	7065_DN
Drug	Clorgyline hydrochloride [17780-75-5]; Down 200; 13uM; PC3; HT_HG-U133A	HIVEP3 TRIO MLLT10 ARID1A MEF2C	1.29e-04	192	58	5	6659_DN
Drug	C75; Down 200; 10uM; MCF7; HT_HG-U133A	VPS9D1 ABL2 AP2B1 TRIO BCL9	1.29e-04	192	58	5	6423_DN
Drug	Beta-sistosterol [83-46-5]; Down 200; 9.6uM; MCF7; HT_HG-U133A	RPAP1 PRR36 CBFA2T2 BCL9 SRCAP	1.32e-04	193	58	5	4154_DN
Drug	Bromperidol [10457-90-6]; Up 200; 9.6uM; MCF7; HT_HG-U133A	HIVEP3 TRIO SRCAP ARID1A MEF2C	1.32e-04	193	58	5	2872_UP
Drug	trichostatin A; Down 200; 0.1uM; ssMCF7; HG-U133A	ACACA DAB2 MLLT10 MED13L ARID1A	1.32e-04	193	58	5	413_DN
Drug	Mexiletine hydrochloride [5370-01-4]; Down 200; 18.6uM; MCF7; HT_HG-U133A	VPS9D1 PRR36 FAM120C CBFA2T2 SRCAP	1.32e-04	193	58	5	3973_DN
Drug	Citalopram hydrobromide [59729-32-7]; Down 200; 1uM; MCF7; HT_HG-U133A	HIVEP3 VPS9D1 ABL2 SRCAP EMSY	1.36e-04	194	58	5	3903_DN
Drug	Equilin [474-86-2]; Down 200; 15uM; MCF7; HT_HG-U133A	VPS9D1 TRIO PRR36 TTLL5 KIF13A	1.36e-04	194	58	5	3377_DN
Drug	Betazole hydrochloride; Up 200; 27uM; PC3; HT_HG-U133A	ACACA AP2B1 MED13L BCL9 EMSY	1.36e-04	194	58	5	1812_UP
Drug	Dicumarol [66-76-2]; Down 200; 11.8uM; MCF7; HT_HG-U133A	HIVEP3 HSPG2 PRR36 CBFA2T2 SRCAP	1.39e-04	195	58	5	3941_DN
Drug	Pentamidine isethionate [140-64-7]; Down 200; 6.8uM; MCF7; HT_HG-U133A	HSPG2 ABL2 WWTR1 ARID1A EMSY	1.39e-04	195	58	5	4396_DN
Drug	Amoxapine [14028-44-5]; Down 200; 12.8uM; MCF7; HT_HG-U133A	RPAP1 TRIO TTLL5 MLLT10 SRCAP	1.39e-04	195	58	5	4996_DN
Drug	Flunisolide [3385-03-3]; Down 200; 9.2uM; MCF7; HT_HG-U133A	AP2B1 TRIO PRR36 CBFA2T2 SRCAP	1.39e-04	195	58	5	3923_DN
Drug	6-Furfurylaminopurine [525-79-1]; Up 200; 18.6uM; HL60; HT_HG-U133A	KCNH6 TTLL5 DAB2 MECOM WWTR1	1.42e-04	196	58	5	2511_UP
Drug	Iproniazide phosphate [305-33-9]; Down 200; 14.4uM; MCF7; HT_HG-U133A	HIVEP3 ABL2 FAM120C PLAGL1 SRCAP	1.42e-04	196	58	5	2288_DN
Drug	(1-[(4-Chlorophenyl)phenyl-methyl]-4-methylpiperazine) [1620-21-9]; Up 200; 11.8uM; MCF7; HT_HG-U133A	HIVEP3 WWTR1 MAML3 EMSY PRDM1	1.42e-04	196	58	5	6053_UP
Drug	Nadolol [42200-33-9]; Down 200; 13uM; MCF7; HT_HG-U133A	HIVEP3 VPS9D1 FAM120C TTLL5 SRCAP	1.42e-04	196	58	5	3359_DN
Drug	Nystatine [1400-61-9]; Up 200; 4.4uM; MCF7; HT_HG-U133A	KCNH6 FKBP15 TRIO CBFA2T2 ISL1	1.42e-04	196	58	5	4807_UP
Drug	Solanine alpha [20562-02-1]; Up 200; 4.6uM; PC3; HT_HG-U133A	KCNH6 ZC3H13 MLLT10 SRCAP KIF13A	1.42e-04	196	58	5	4087_UP
Drug	Nefopam hydrochloride [23327-57-3]; Down 200; 13.8uM; MCF7; HT_HG-U133A	CBFA2T2 MLLT10 SRCAP KIF13A MEF2C	1.42e-04	196	58	5	4752_DN
Drug	Pregnenolone [145-13-1]; Down 200; 12.6uM; MCF7; HT_HG-U133A	HIVEP3 FAM120C TTLL5 MLLT10 BCL9	1.42e-04	196	58	5	4802_DN
Drug	Ampyrone [83-07-8]; Down 200; 19.6uM; MCF7; HT_HG-U133A	AP2B1 TRIO TTLL5 SRCAP KIF13A	1.42e-04	196	58	5	2249_DN
Drug	Benzonatate [104-31-4]; Down 200; 6.6uM; MCF7; HT_HG-U133A	RPAP1 PRR36 PLAGL1 WWTR1 BCL9	1.42e-04	196	58	5	1679_DN
Drug	NS-398; Up 200; 10uM; MCF7; HT_HG-U133A	CBFA2T2 PLAGL1 WWTR1 MLLT10 KIF13A	1.42e-04	196	58	5	6911_UP
Drug	Etilefrine hydrochloride [534-87-2]; Down 200; 18.4uM; MCF7; HT_HG-U133A	HIVEP3 ABL2 FAM120C CBFA2T2 SRCAP	1.42e-04	196	58	5	4415_DN
Drug	6,7-dimethoxy-2-(pyrrolidin-1-yl)-N-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine	DNHD1 ERICH3 PRR36 SRCAP	1.44e-04	104	58	4	ctd:C000595015
Drug	Betonicine [515-25-3]; Down 200; 25.2uM; MCF7; HT_HG-U133A	TRIO FAM120C ZC3H13 ARID1A EMSY	1.46e-04	197	58	5	4767_DN
Drug	Riluzole hydrochloride; Up 200; 14.8uM; PC3; HT_HG-U133A	VPS9D1 AP2B1 TRIO ZC3H13 MLLT10	1.46e-04	197	58	5	3666_UP
Drug	rosiglitazone; Up 200; 10uM; MCF7; HT_HG-U133A_EA	AP2B1 SMARCC2 MLLT10 ARID1A ITPR3	1.46e-04	197	58	5	1071_UP
Drug	Glibenclamide [10238-21-8]; Down 200; 8uM; MCF7; HT_HG-U133A	CBFA2T2 MECOM PLAGL1 WWTR1 BCL9	1.46e-04	197	58	5	7202_DN
Drug	Ketoprofen [22071-15-4]; Down 200; 15.8uM; MCF7; HT_HG-U133A	ABL2 TTLL5 PLAGL1 BCL9 ARID1A	1.46e-04	197	58	5	4751_DN
Drug	Primidone [125-33-7]; Down 200; 18.4uM; HL60; HT_HG-U133A	VPS9D1 ABL2 TRIO WWTR1 ITPR3	1.46e-04	197	58	5	3065_DN
Drug	C75; Down 200; 10uM; PC3; HT_HG-U133A	CBFA2T2 TTLL5 SMARCC2 MLLT10 SRCAP	1.46e-04	197	58	5	6428_DN
Drug	15(S)-15-methyl Prostaglandin E2; Up 200; 10uM; MCF7; HT_HG-U133A	HIVEP3 TRIO ZC3H13 TTLL5 PLAGL1	1.46e-04	197	58	5	7521_UP
Drug	Amphotericin B [1397-89-3]; Up 200; 4.4uM; MCF7; HT_HG-U133A	VPS9D1 ZC3H13 CBFA2T2 PLAGL1 PRDM1	1.46e-04	197	58	5	3303_UP
Drug	Piromidic acid [19562-30-2]; Down 200; 13.8uM; MCF7; HT_HG-U133A	HIVEP3 RPAP1 PRR36 PLAGL1 BCL9	1.46e-04	197	58	5	3335_DN
Drug	Ethamivan [304-84-7]; Up 200; 18uM; PC3; HT_HG-U133A	HIVEP3 AP2B1 FAM120C MAML3 EMSY	1.46e-04	197	58	5	7260_UP
Drug	2-propylpentanoic acid; Down 200; 500uM; PC3; HT_HG-U133A	AP2B1 FAM120C NFYC WWTR1 MLLT10	1.46e-04	197	58	5	1240_DN
Drug	Chlorpheniramine maleate [113-92-8]; Up 200; 10.2uM; HL60; HG-U133A	SMARCC2 PLAGL1 MED13L SRCAP ARID1A	1.46e-04	197	58	5	1371_UP
Drug	Dienestrol [84-17-3]; Up 200; 15uM; PC3; HT_HG-U133A	KCNH6 ABL2 MLLT10 SRCAP MEF2C	1.49e-04	198	58	5	5727_UP
Drug	Proxyphylline [603-00-9]; Up 200; 16.8uM; MCF7; HT_HG-U133A	CBFA2T2 SRCAP ARID1A MEF2C ITPR3	1.49e-04	198	58	5	6494_UP
Drug	Diphenylpyraline hydrochloride [132-18-3]; Up 200; 12.6uM; PC3; HT_HG-U133A	VPS9D1 KCNH6 ABL2 PRR36 SRCAP	1.49e-04	198	58	5	3743_UP
Drug	Niridazole [61-57-4]; Up 200; 18.6uM; MCF7; HT_HG-U133A	HIVEP3 VPS9D1 ABL2 EMSY PRDM1	1.49e-04	198	58	5	5682_UP
Drug	Vitamin K2 [11032-49-8]; Down 200; 9uM; MCF7; HT_HG-U133A	HIVEP3 VPS9D1 FKBP15 FAM120C CBFA2T2	1.49e-04	198	58	5	3880_DN
Drug	Quinic acid [86-68-0]; Down 200; 19.6uM; MCF7; HT_HG-U133A	ABL2 PLAGL1 ARID1A KIF13A EMSY	1.49e-04	198	58	5	3540_DN
Drug	DO 897/99; Up 200; 8.2uM; MCF7; HT_HG-U133A	VPS9D1 TRIO FAM120C TTLL5 ITPR3	1.49e-04	198	58	5	7462_UP
Drug	DL-PPMP; Up 200; 2uM; MCF7; HT_HG-U133A_EA	TRIO CBFA2T2 TTLL5 SMARCC2 MED13L	1.49e-04	198	58	5	1121_UP
Drug	Zidovudine, AZT [30516-87-1]; Up 200; 15uM; MCF7; HT_HG-U133A	HIVEP3 CBFA2T2 PLAGL1 SRCAP ARID1A	1.49e-04	198	58	5	3211_UP
Drug	diclofenac sodium; Down 200; 10uM; PC3; HG-U133A	ACACA TRIO SMARCC2 BCL9 MEF2C	1.49e-04	198	58	5	445_DN
Drug	11-deoxy-16,16-dimethyl Prostaglandin E2; Down 200; 10uM; PC3; HT_HG-U133A	HIVEP3 TTLL5 WWTR1 KIF13A EMSY	1.49e-04	198	58	5	7519_DN
Drug	Metampicillin sodium salt [6489-61-8]; Down 200; 10.4uM; MCF7; HT_HG-U133A	VPS9D1 TRIO TTLL5 SRCAP KIF13A	1.49e-04	198	58	5	2286_DN
Drug	Deltaline [6836-11-9]; Up 200; 7.8uM; MCF7; HT_HG-U133A	HIVEP3 HSPG2 TRIO DAB2 SRCAP	1.49e-04	198	58	5	3831_UP
Drug	Folic acid [59-30-3]; Down 200; 9uM; PC3; HT_HG-U133A	HIVEP3 AP2B1 TRIO SMARCC2 ITPR3	1.53e-04	199	58	5	5844_DN
Drug	3-aminobenzamide; Down 200; 10000uM; MCF7; HG-U133A	DLAT SMARCC2 WWTR1 SRCAP TP53BP1	1.53e-04	199	58	5	590_DN
Drug	Oxalamine citrate salt [1949-20-8]; Down 200; 9.2uM; PC3; HT_HG-U133A	FKBP15 TRIO FAM120C CBFA2T2 BCL9	1.53e-04	199	58	5	6624_DN
Drug	Moxisylyte hydrochoride [964-52-3]; Down 200; 12.6uM; MCF7; HT_HG-U133A	RPAP1 TTLL5 WWTR1 BCL9 SRCAP	1.56e-04	200	58	5	1682_DN
Drug	Promazine hydrochloride [53-60-1]; Up 200; 12.4uM; MCF7; HT_HG-U133A	ZC3H13 CBFA2T2 MLLT10 SRCAP EMSY	1.56e-04	200	58	5	3833_UP
Drug	Thiamphenicol [15318-45-3]; Up 200; 11.2uM; MCF7; HT_HG-U133A	VPS9D1 PLAGL1 WWTR1 KIF13A EMSY	1.56e-04	200	58	5	1704_UP
Drug	Bendroflumethiazide [73-48-3]; Up 200; 9.4uM; MCF7; HT_HG-U133A	HIVEP3 CBFA2T2 SRCAP ITPR3 PRDM1	1.56e-04	200	58	5	3840_UP
Drug	Nifurtimox [23256-30-6]; Up 200; 14uM; MCF7; HT_HG-U133A	VPS9D1 TRIO CBFA2T2 TTLL5 SRCAP	1.56e-04	200	58	5	4953_UP
Drug	SB 203580; Up 200; 1uM; MCF7; HT_HG-U133A	VPS9D1 RPAP1 PLAGL1 MLLT10 KIF13A	1.56e-04	200	58	5	6899_UP
Drug	1,4-bis-(phenoxyacetyl)piperazine	AP2B1 DAB2 MECOM UNC13D MLLT10	2.70e-04	225	58	5	CID001008511
Drug	Succimer	HIVEP3 ZNF296 ZC3H13 CBFA2T2 DAB2 DLAT MECOM MLLT10 MEF2C SPATA13 PRDM1	3.02e-04	1264	58	11	ctd:D004113
Drug	Magnetite Nanoparticles	HIVEP3 ZNF296 ZC3H13 CBFA2T2 DAB2 DLAT MECOM MLLT10 MEF2C SPATA13 PRDM1	4.10e-04	1310	58	11	ctd:D058185
Drug	irinotecan HCl; Down 200; 100uM; PC3; HT_HG-U133A	TRIO ANKRD17 MED13L MEF2C	9.50e-04	171	58	4	7535_DN
Drug	I-Hg	CBFA2T2 GCSAM	1.06e-03	19	58	2	CID000447029
Drug	STOCK1N-35215; Up 200; 10uM; PC3; HT_HG-U133A	FKBP15 ABL2 TRIO KIF13A	1.20e-03	182	58	4	6427_UP
Drug	17-AAG; Up 200; 1uM; PC3; HT_HG-U133A	FKBP15 ABL2 MLLT10 EMSY	1.22e-03	183	58	4	1206_UP
Drug	F0447-0125; Down 200; 10uM; PC3; HT_HG-U133A	CBFA2T2 TTLL5 WWTR1 MLLT10	1.25e-03	184	58	4	6429_DN
Drug	0179445-0000 [211246-22-9]; Up 200; 10uM; MCF7; HT_HG-U133A	KCNH6 ABL2 FAM120C SRCAP	1.25e-03	184	58	4	4755_UP
Drug	Clomiphene citrate (Z,E) [50-41-9]; Up 200; 6.6uM; MCF7; HT_HG-U133A	VPS9D1 TRIO MECOM SRCAP	1.25e-03	184	58	4	4994_UP
Drug	ICI 182,780; Down 200; 1uM; MCF7; HT_HG-U133A	AP2B1 TRIO DLAT MED13L	1.27e-03	185	58	4	6965_DN
Drug	17-AAG; Down 200; 1uM; MCF7; HT_HG-U133A	FAM120C SMARCC2 MECOM BCL9	1.27e-03	185	58	4	5585_DN
Drug	Withaferin A [5119-48-2]; Down 200; 1uM; MCF7; HT_HG-U133A	HIVEP3 FAM120C TTLL5 MECOM	1.30e-03	186	58	4	3902_DN
Drug	TPGS	DLAT MLLT10	1.30e-03	21	58	2	CID000071406
Drug	Levonordefrin [829-74-3]; Up 200; 21.8uM; PC3; HT_HG-U133A	TRIO CBFA2T2 MLLT10 KIF13A	1.32e-03	187	58	4	5854_UP
Disease	Neurodevelopmental Disorders	HIVEP3 TRIO MED13L SRCAP MEF2C	1.03e-06	93	57	5	C1535926
Disease	Coffin-Siris syndrome (implicated_via_orthology)	SMARCC2 ARID1A	1.31e-04	9	57	2	DOID:1925 (implicated_via_orthology)
Disease	ascending aortic diameter	HIVEP3 UNC13D MED13L MBD5	1.58e-04	140	57	4	EFO_0021787
Disease	adult onset asthma, body mass index	UNC13D PLAGL1	1.63e-04	10	57	2	EFO_0004340, EFO_1002011
Disease	Coffin-Siris syndrome	SMARCC2 ARID1A	2.82e-04	13	57	2	C0265338
Disease	liver volume	ARID1A TP53BP1	3.79e-04	15	57	2	EFO_0600048
Disease	monocyte percentage of leukocytes	RASAL3 MECOM PLAGL1 MED13L MBD5 ARID1A MEF2C	5.02e-04	731	57	7	EFO_0007989
Disease	eosinophil count	SPATC1 HIVEP3 RASAL3 UNC13D PLAGL1 MBD5 EMSY TP53BP1 GCSAM ITPR3	5.10e-04	1488	57	10	EFO_0004842
Disease	multisite chronic pain	MLLT10 MAML3 ITPR3	8.34e-04	95	57	3	EFO_0010100
Disease	Adenoid Cystic Carcinoma	SRCAP ARID1A MAML3	9.68e-04	100	57	3	C0010606
Disease	multiple myeloma	SOHLH2 MECOM SRCAP	1.34e-03	112	57	3	EFO_0001378
Disease	glomerular filtration rate, response to platinum based chemotherapy	WWTR1 BCL9	1.34e-03	28	57	2	EFO_0004647, EFO_0005208
Disease	adult onset asthma	UNC13D PLAGL1 EMSY	1.56e-03	118	57	3	EFO_1002011
Disease	seasonal allergic rhinitis	ABL2 EMSY	1.75e-03	32	57	2	EFO_0003956
Disease	Acute Myeloid Leukemia, M1	TRIO MECOM MLLT10	1.84e-03	125	57	3	C0026998
Disease	Acute Myeloid Leukemia (AML-M2)	TRIO MECOM MLLT10	1.84e-03	125	57	3	C1879321
Disease	chronic obstructive pulmonary disease	RPAP1 MECOM BCL9 KIF13A MAML3 EMSY	2.08e-03	688	57	6	EFO_0000341
Disease	ovarian neoplasm	MECOM BCL9 TP53BP1	2.24e-03	134	57	3	C0919267
Disease	Malignant neoplasm of ovary	MECOM BCL9 TP53BP1	2.39e-03	137	57	3	C1140680
Disease	Conventional (Clear Cell) Renal Cell Carcinoma	DNHD1 MLLT10 ARID1A	2.97e-03	148	57	3	C0279702
Disease	retinal vasculature measurement	HSPG2 TRIO TTLL5 MED13L MEF2C	3.21e-03	517	57	5	EFO_0010554
Disease	Neuroblastoma	ISL1 ARID1A	3.75e-03	47	57	2	C0027819

Protein segments in the cluster

Peptide	Gene	Start	Entry
RSVENNMPILSPHPP	ERICH3	111	Q5RHP9
PSTPLAIHTPLMPNQ	AP2B1	766	P63010
PPPVMRLLQHPSICS	ABL2	986	P42684
PSPHMPRPNQTILVD	BRICD5	71	Q6PL45
QFMLPTSHPNRGNIP	ACACA	1181	Q13085
ISSHFLQQPRPLMAP	GCSAM	156	Q8N6F7
SPSHPQPLSPEQMLQ	FAM186B	186	Q8IYM0
RPHLPMSPSTQQPAL	FAM186B	591	Q8IYM0
HSQATQPMLILLPPP	DNHD1	4081	Q96M86
PLSPARATNSPKPHM	ANKRD17	1931	O75179
NGLPLIPMPQSLRSS	CC2D2B	631	Q6DHV5
KLMATPNPSNVHPAL	RBPMS2	116	Q6ZRY4
VPMRLPLPPAQVHSS	RASAL3	746	Q86YV0
TIMRQPPVTHAPQPL	HSPG2	261	P98160
RLPNNHSTASPLGMP	ITPR3	2401	Q14573
SPLMTHPQILPATQD	MECOM	526	Q03112
PSMQNHIPQVSSPAP	ARID1A	1576	O14497
TQPPSMHSSLLVTPP	DAB2	606	P98082
NLNPMDSPHSPISPL	MED13L	541	Q71F56
LQRMFPTPPSLEQHP	MED13L	861	Q71F56
LPSNMPLPSASPLHQ	MAML3	206	Q96JK9
PELLQEMPPRHSPQS	KCNH6	796	Q9H252
APRHSPALTVPLMNP	CBFA2T2	266	O43439
HQKVPLPSLSPTMQA	DLAT	91	P10515
HPALPQMTSQAPQPS	FKBP15	416	Q5T1M5
PLAHPSLQRNSMSPG	MEF2C	171	Q06413
LPGMTSLSPLHPSQQ	NFYC	406	Q13952
PKQPMELHNLSSPSP	OXER1	36	Q8TDS5
LNPMAPPSRQGSELH	ERVK-10	251	P87889
NSRLSHMPPLPLNPS	BCL9	811	O00512
PSMLNPANVPTHLLL	FAM120C	751	Q9NX05
SQASVPQPASPLMHI	DDX12P	571	Q92771
MALGNSLHPNPPQSR	MBD5	801	Q9P267
QSIANSLPPHMSPVK	EMSY	246	Q7Z589
RPLLSQESMPPPQAH	KIF13A	1486	Q9H1H9
HSLTLSPPEQAAQPM	PLAGL1	261	Q9UM63
TLAMPPRSSIQHARP	NHSL2	901	Q5HYW2
SHSPQAPLSSLIMPP	PRR36	696	Q9H6K5
HVQRLSPTMNPALNP	SLITRK2	281	Q9H156
LPHPMLNPTSLPSSL	PRDM1	456	O75626
PLSPLHPARPLQMAA	ISL1	146	P61371
MQSSPSPAHPQLPVL	SRCAP	1	Q6ZRS2
PVSMANPLHPNLPAT	SMARCC2	1136	Q8TAQ2
NPLHPNLPATTTMPS	SMARCC2	1141	Q8TAQ2
MSQNPTPLTHTTVPP	MLLT10	926	P55197
LSHMTAINNVPPPPL	CNBD1	11	Q8NA66
LTQPASRPPMPAHQV	SPATA13	46	Q96N96
SRMHNSPTQNLPVPH	SPATC1	366	Q76KD6
RNPTLTMGQPRTPHS	TNS4	336	Q8IZW8
TAPPVPLLRSHSMPS	HIVEP3	531	Q5T1R4
HTIRQSQQPMKPISP	TP53BP1	1081	Q12888
PRELSTHPPQPLSMQ	RPAP1	706	Q9BWH6
THPPQPLSMQRIASL	RPAP1	711	Q9BWH6
RPSQSLHCMLSPPEP	VPS9D1	326	Q9Y2B5
TNQNISIHLPSAMPP	SOHLH2	381	Q9NX45
SQPVPAMSRNPDHNL	PXT1	46	Q8NFP0
MATLLSHPQQRPPFL	UNC13D	1	Q70J99
IPSAIPSMPHQPTIL	TTLL5	921	Q6EMB2
SPQRKQSPPRHRSPM	ZC3H13	381	Q5T200
PPMAIQQHSLLQPDS	TRIO	1871	O75962
MNLHPAVSSTPVPQR	WWTR1	166	Q9GZV5
HRQVPPQSPLMADTS	ZNF296	281	Q8WUU4